190 related articles for article (PubMed ID: 32990482)
1. Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
Abu El-Asrar AM; Dheyab A; Khatib D; Struyf S; Van Damme J; Opdenakker G
Ocul Immunol Inflamm; 2022 Apr; 30(3):750-757. PubMed ID: 32990482
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment.
Bolletta E; Gozzi F; Mastrofilippo V; Pipitone N; De Simone L; Croci S; Invernizzi A; Adani C; Iannetta D; Coassin M; Fontana L; Salvarani C; Cimino L
Ocul Immunol Inflamm; 2022 Aug; 30(6):1303-1308. PubMed ID: 33793383
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease.
Tobaigy MF; AlBloushi AF; Al-Dhibi HA
Ocul Immunol Inflamm; 2024 May; 32(4):424-428. PubMed ID: 36657743
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
5. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.
Umran RMR; Shukur ZYH
Mod Rheumatol; 2018 Jan; 28(1):197-199. PubMed ID: 26154298
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A
Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
11. Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group.
AlBloushi AF; AlEnezi SH; Al Owaifeer AM; Al-Hadlaq OS; Gikandi PW; Abu El-Asrar AM
Ocul Immunol Inflamm; 2022; 30(7-8):1669-1677. PubMed ID: 34184966
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Recurrent Anterior Uveitis in Initial Acute-Onset Vogt-Koyanagi-Harada Disease.
Lim YJ; Byon I; Kim HW; Park SW; Kwon HJ; Kim E
Korean J Ophthalmol; 2023 Aug; 37(4):299-306. PubMed ID: 37400085
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis.
Elhamaky TR
Indian J Ophthalmol; 2022 Jul; 70(7):2465-2470. PubMed ID: 35791135
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.
Kryshtalskyj MT; Roy M
Ocul Immunol Inflamm; 2022 May; 30(4):894-900. PubMed ID: 33621146
[TBL] [Abstract][Full Text] [Related]
15. Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.
Namba K; Takase H; Usui Y; Nitta F; Maruyama K; Kusuhara S; Takeuchi M; Azumi A; Yanai R; Kaneko Y; Hasegawa E; Nakai K; Tsuruga H; Morita K; Kaburaki T
Jpn J Ophthalmol; 2022 Mar; 66(2):130-141. PubMed ID: 35044561
[TBL] [Abstract][Full Text] [Related]
16. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
17. Vogt-Koyanagi-Harada syndrome and pregnancy.
Steahly LP
Ann Ophthalmol; 1990 Feb; 22(2):59-62. PubMed ID: 2316953
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunosuppressive therapy on oxygen saturation and diameter of retinal vessels in initial onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Alotaibi MD; Gikandi PW; Stefánsson E
Acta Ophthalmol; 2021 Feb; 99(1):75-82. PubMed ID: 32592327
[TBL] [Abstract][Full Text] [Related]
19. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
20. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
